These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1322 related items for PubMed ID: 23771985
1. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S, Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985 [Abstract] [Full Text] [Related]
2. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P. Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070 [Abstract] [Full Text] [Related]
3. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. Patriarca F, Medeot M, Isola M, Battista ML, Sperotto A, Pipan C, Toffoletti E, Dozzo M, Michelutti A, Gregoraci G, Geromin A, Cerno M, Savignano C, Rinaldi C, Barbone F, Fanin R. Transpl Infect Dis; 2013 Jun; 15(3):259-67. PubMed ID: 23405972 [Abstract] [Full Text] [Related]
4. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation. Zallio F, Primon V, Tamiazzo S, Pini M, Baraldi A, Corsetti MT, Gotta F, Bertassello C, Salvi F, Rocchetti A, Levis A. Clin Transplant; 2013 Jun; 27(4):E491-7. PubMed ID: 23781897 [Abstract] [Full Text] [Related]
5. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation. Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, Gualandi F, Bregante S, Ibatici A, di Grazia C, Dominietto A, Varaldo R, Bruno B, Frassoni F, Van Lint MT, Bacigalupo A. Biol Blood Marrow Transplant; 2011 Jun; 17(6):901-7. PubMed ID: 20950702 [Abstract] [Full Text] [Related]
6. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Styczynski J, Einsele H, Gil L, Ljungman P. Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376 [Abstract] [Full Text] [Related]
7. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K. Scand J Infect Dis; 2007 Oct; 39(3):235-44. PubMed ID: 17366054 [Abstract] [Full Text] [Related]
8. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment. Chiereghin A, Prete A, Belotti T, Gibertoni D, Piccirilli G, Gabrielli L, Pession A, Lazzarotto T. Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232 [Abstract] [Full Text] [Related]
9. Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation. Xuan L, Jiang X, Sun J, Zhang Y, Huang F, Fan Z, Guo X, Dai M, Liu C, Yu G, Zhang X, Wu M, Huang X, Liu Q. Transplantation; 2013 Sep; 96(6):560-6. PubMed ID: 23842192 [Abstract] [Full Text] [Related]
10. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation. Ruf S, Behnke-Hall K, Gruhn B, Bauer J, Horn M, Beck J, Reiter A, Wagner HJ. J Clin Virol; 2012 Mar; 53(3):186-94. PubMed ID: 22182950 [Abstract] [Full Text] [Related]
11. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies. Gao XN, Lin J, Wang LJ, Li F, Li HH, Wang SH, Huang WR, Gao CJ, Yu L, Liu DH. Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569 [Abstract] [Full Text] [Related]
12. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention? Greenfield HM, Gharib MI, Turner AJ, Guiver M, Carr T, Will AM, Wynn RF. Pediatr Blood Cancer; 2006 Aug; 47(2):200-5. PubMed ID: 16206207 [Abstract] [Full Text] [Related]
13. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P. J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094 [Abstract] [Full Text] [Related]
14. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation. Carpenter B, Haque T, Dimopoulou M, Atkinson C, Roughton M, Grace S, Denovan S, Fielding A, Kottaridis PD, Griffiths P, Mackinnon S, Emery V, Chakraverty R. Transplantation; 2010 Sep 15; 90(5):564-70. PubMed ID: 20555307 [Abstract] [Full Text] [Related]
15. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. Meerbach A, Wutzler P, Häfer R, Zintl F, Gruhn B. J Med Virol; 2008 Mar 15; 80(3):441-54. PubMed ID: 18205222 [Abstract] [Full Text] [Related]
16. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation. Kalra A, Roessner C, Jupp J, Williamson T, Tellier R, Chaudhry A, Khan F, Taparia M, Jimenez-Zepeda VH, Stewart DA, Daly A, Storek J. Clin Transplant; 2018 Jan 15; 32(1):. PubMed ID: 29114932 [Abstract] [Full Text] [Related]
17. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation. Ahmad I, Cau NV, Kwan J, Maaroufi Y, Meuleman N, Aoun M, Lewalle P, Martiat P, Crokaert F, Bron D. Transplantation; 2009 Apr 27; 87(8):1240-5. PubMed ID: 19384173 [Abstract] [Full Text] [Related]
18. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation. Kim BK, Kang HJ, Hong KT, An HY, Choi JY, Lee JS, Park SS, Shin HY. Transpl Infect Dis; 2019 Dec 27; 21(6):e13182. PubMed ID: 31556214 [Abstract] [Full Text] [Related]
19. Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges. Kittan NA, Beier F, Kurz K, Niller HH, Egger L, Jilg W, Andreesen R, Holler E, Hildebrandt GC. Transpl Infect Dis; 2011 Oct 27; 13(5):524-30. PubMed ID: 21395956 [Abstract] [Full Text] [Related]
20. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients. Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Yegitbasi M, Reinke P, Kebelmann-Betzig C, Hauptmann K, Gross-Wieltsch U, Hetzer R, Berger F. Pediatr Transplant; 2009 Feb 27; 13(1):54-62. PubMed ID: 18518912 [Abstract] [Full Text] [Related] Page: [Next] [New Search]